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AbstrAct
Diffuse intrinsic pontine gliomas (DIPGs) have a dismal prognosis and are poorly 
understood brain cancers. Receptor tyrosine kinases stabilized by neuron-glial antigen 
2 (NG2) protein are known to induce gliomagenesis. Here, we investigated NG2 
expression in a cohort of DIPG specimens (n= 50). We demonstrate NG2 expression in 
the majority of DIPG specimens tested and determine that tumors harboring histone 
3.3 mutation express the highest NG2 levels. We further demonstrate that microRNA 
129-2 (miR129-2) is downregulated and hypermethylated in human DIPGs, resulting 
in the increased expression of NG2. Treatment with 5-Azacytidine, a methyltransferase 
inhibitor, results in NG2 downregulation in DIPG primary tumor cells in vitro. NG2 
expression is altered (symmetric segregation) in mitotic human DIPG and mouse 
tumor cells. These mitotic cells co-express oligodendrocyte (Olig2) and astrocyte (glial 
fibrillary acidic protein, GFAP) markers, indicating lack of terminal differentiation. NG2 
knockdown retards cellular migration in vitro, while NG2 expressing neurospheres 
are highly tumorigenic in vivo, resulting in rapid growth of pontine tumors. NG2 
expression is targetable in vivo using miR129-2 indicating a potential avenue for 
therapeutic interventions.  This data implicates NG2 as a molecule of interest in DIPGs 
especially those with H3.3 mutation.
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IntroductIon
Pediatric brainstem gliomas (BSGs) account 
for 15% of all brain tumors in children [1]. Diffuse 
intrinsic pontine gliomas (DIPGs) are high grade 
tumors of pons with the peak age of onset of 6-7 years 
[2]. Children diagnosed with DIPG have less than 90% 
chance of survival within two years of diagnosis [3, 4]. 
A pLys27Met (K27M) driver mutation in the H3F3A 
gene of histone 3 variant 3 (H3.3) and HIST1H3B (H3.1) 
was recently correlated to a subgroup of DIPG patients 
with distinct clinical and biological characteristics 
[5]. Other genomic aberrations of DIPGs include p53 
mutations and amplification of tyrosine receptor kinase/
Ras/phosphatidylinositol 3-kinase signaling pathways 
including platelet derived growth factor receptor alpha 
(PDGFRα) [6]. Our group and others have reported the 
involvement of Hedgehog (Hh) signaling pathway in a 
subset of DIPGs [7, 8]. Modulation of Hh and tyrosine 
kinase receptors may alter the self-renewal properties of 
DIPG cells by targeting the self-renewing cancer stem 
cells (CSC). Receptor tyrosine kinases including PDGFRα 
are stabilized by the transmembrane protein NG2, also 
known as chondroitin sulfate proteoglycan 4 (CSPG4) [9]. 
NG2+ cells that often co-express PDGFRα and Olig-2 are 
present in adult gliomas [10-12], where NG2 contributes 
to the neoplastic transformation of glioma precursor cells 
[13]. NG2 segregation in dividing oligodendrocytes plays 
an important role in terminal differentiation and self-
renewal properties of these cells [13]. Specifically, in non-
neoplastic tissue, NG2 expression is limited to only one 
daughter cell. In contrast, in malignant gliomas, NG2 is 
symmetrically expressed in both daughter cells resulting 
in active expression of other growth factor receptors 
including epidermal growth factor receptor (EGFR) [13]. 
Despite the potential role of NG2 in EGFR-mediated 
neoplasm, NG2 expression has not been previously 
established in pediatric gliomas. We have recently reported 
elevated mRNA expression of NG2 in a large percentage 
of pediatric DIPGs [8]. 
In this study, we determined that NG2 expression is 
prominent in a majority of our DIPG cohort (n=34) as well 
as in vitro and in vivo models of DIPG. Our study is the 
first to demonstrate that: i) NG2 expression is associated 
with DIPG; ii) NG2 expression is symmetric in mitotic 
cells resulting in uncommitted progenitors with CSC 
properties; iii) NG2 in DIPGs is regulated by miR129-2; 
and iv) NG2 expression can be targeted in vivo and in vitro 
using miR129-2. Orthotopic injection of NG2 expressing 
cells results in rapidly developing pontine tumors that 
co-express PDGFRα, PDGFRβ and Ki67. Identification 
of NG2 as a protein associated with DIPG may provide 
novel avenues for development of therapeutic targets to 
stop proliferation of this highly infiltrative cancer. 
results
nG2 is upregulated in Human dIPG
To investigate NG2 expression in DIPGs, we 
performed immunohistochemical (IHC) staining on 
formalin fixed paraffin embedded (FFPE) specimens 
from DIPG children obtained at postmortem. Histological 
studies by a neuropathologist indicated NG2 protein 
upregulation in tumor (Figure 1a), where NG2 was 
localized to the cell membrane as expected (Figure 1a, 
inset). NG2 expression was not detected in adjacent 
normal human brainstem (Figure 1b). To define the 
frequency of NG2 expression in DIPGs, we used a larger 
cohort (n = 50) of human specimens (Supplementary Table 
1) for immunohistochemical (IHC) and Western blotting 
assays. IHC assays using formalin fixed specimens 
showed NG2 expression in 75% (9 of 12) of DIPGs, 
with variable expression levels localized to tumor cells 
(Supplementary Table 2). To quantify NG2 upregulation, 
protein extracts from frozen human DIPG specimens 
were used for Western blotting assays (Supplementary 
Figure 1). NG2 expression in protein extract from 38 
human specimens (22 DIPG and 16 adjacent normal) 
validated NG2 expression in DIPGs [13 of 22 (60 %)] to 
varying degrees. Low NG2 expression was also detected 
in four adjacent normal tissue specimens (Supplementary 
Figure 1). This could be attributed to the presence of 
infiltrating glioma cells or normal NG2 expressing cells 
within normal brainstem (Supplementary Figure 1). NG2 
expression was assessed using densitometry and found to 
be significant (average fold change = 3, p < 0.05) in tumor 
compared to normal specimens (Figure 1c). 
Mutation of the HIST1H3B and H3F3A genes, 
encoding histones 3.1 (H3.1) and 3.3 (H3.3) respectively, 
have been implicated in pediatric DIPGs [5, 14, 15]. We 
inspected the correlation of NG2 expression with H3 
mutations status in our DIPG cohort (n = 13). We found 
NG2 to be significantly (p = 0.035) upregulated in H3.3 
mutant specimens when compared with specimens with 
H3.1 mutation (Figure 1d). No NG2 expression was 
detected in the only DIPG specimen with wild type histone 
3 status. 
nG2 expression is upregulated in Preclinical 
dIPG Models
To test NG2 expression in preclinical DIPG murine 
models, we used IHC to assess NG2 expression in the 
PDGFB-Ink4a-ARF-/- mouse (PDGFB model) [16] as well 
as mouse injected with glioma cells derived from PDGFB/
p53-/-/H3.3K27M model [17]. We show significant 
upregulation of NG2 in both PDGFB (Figure 2a) and 
PDGFB/p53-/-/H3.3K27M (Figure 2c) DIPG mouse 
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models. Low NG2 expression was detected in normal 
adjacent brainstem regions as well as the cerebellum 
(Figure 2b, 2d). High level (148 fold, p < 0.05) of NG2 
was also detected by Western blot assays using tumor (n = 
3) and normal (n = 3) brainstem specimens obtained from 
PDGFB mouse model or healthy controls (Supplementary 
Figure 2a). Furthermore, we tested NG2 expression in 
three primary human DIPG lines (SF8628, SUDIPGIV 
and SUDIPGVI) (Supplementary Figure 2b). All three 
primary cells showed NG2 expression as assessed by 
Western blotting assays. 
nG2 is regulated by micrornA 129-2
To investigate potential molecular mechanism of 
NG2 regulation, we used Ingenuity Pathway Analysis 
(IPA) software, which generates biologic pathways based 
on published molecular interactions [8]. IPA analysis 
identified miR129-2 as a potential NG2 regulator. To 
validate NG2 as a target for miR129-2, we transfected 
PDGFB mouse neurospheres with a vector containing 
the 3’-UTR sequence of NG2 cloned downstream of the 
firefly luciferase gene (Luc-3’UTR) along with a plasmid 
vector containing miR129-2. We found that co-expression 
of Luc-3’UTR and miR129-2 results in significant 
downregulation of luciferase expression as compared to 
cells transfected with luc-3’UTR vector alone (Figure 
3a). Moreover, transient transfection of PDGFB mouse 
tumor cells with NG2-targeting shRNA or miR129-2 
expressing plasmid resulted in downregulation [(76% and 
63%, respectively) as compared to control shRNA treated 
or empty vector treated cells] of NG2 protein as assessed 
by Western blot assay, validating the role of miR129-2 in 
Figure 1: Immunohistochemical and western blotting analysis validates nG2 upregulation in human dIPG. (a) In 
human tissue, diffuse expression of NG2 was observed in DIPG tumor localized to membrane (inset). (b) Adjacent healthy brainstem 
tissue. Scale bar: 100 µM. (c) Graphical representation of western blotting data of NG2 expression in 22 DIPG tumor and 16 adjacent 
normal specimens. GAPDH was used for protein loading normalization. Average NG2 expression was plotted after normalizing NG2 levels 
to GAPDH in each sample. P < 0.05 was considered significant. (d) Average of normalized NG2 expression levels in NG2 western blot 
samples with histone 3.1 K27M mutation or histone 3.3 K27M mutation. P < 0.05 was considered significant.
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regulation of NG2 expression (Figure 3b). 
mir129-2 regulates nG2 in Human dIPGs
To validate miR129-2 mediated NG2 targeting in 
human DIPG, we used primary DIPG lines (SF8628). 
Human DIPG cells were transduced with pCDH-control 
or pCDH-miR129-2 lentivirus. Immunofluorescence 
analysis by confocal microscopy revealed upregulation 
of miR129-2 (indicated by GFP), which resulted in NG2 
(red) downregulation in vitro when compared to control 
transduced cells (Figure 3c). 
To investigate miR129-2 expression pattern in 
human DIPGs, we extracted total RNA from 7 tumor and 
7 normal samples in our DIPG cohort and performed RT-
PCR using miR129-2 primers (Figure 3d). We detected 
downregulation of miR129-2 in 85.7% (6 of 7) of DIPG 
tumors compared to normal tissue (average FC = -30.79, 
n=7 pairs). In five of these patients, RT-PCR generated 
miR129-2 expression levels corresponded with levels 
detected via whole transcriptome analysis of the same 
DIPG cohort (average FC = -2, n=7 pairs) [8]. We 
recently generated the comprehensive DNA methylation 
profiles of human DIPG specimens and their perilesional 
normal sections (n=9 pairs) [8]. To determine whether 
miR129-2 is hypermethylated in DIPGs, we inspected 
methylation patterns at 8 CpG loci corresponding to the 
miR129-2 promoter in DIPG specimens. We found overall 
hypermethylation in 66.6 % of specimens (6 of 9) with an 
overall average fold change in expression of 1.30 (tumor 
vs. normal, n=9 pairs, Figure 3d). Hypermethylation 
(at > 4 CpG sites) corresponded to decreased miR129-
2 expression in 57% (4 of 7) of these patients (Figure 
3d). Importantly, 71.4 % (5 of 7) of patients with 
downregulated miR129-2 expression also demonstrated 
NG2 upregulation at the gene (Figure 3d) or protein level 
in whole transcriptome and proteomic analysis. 
nG2 expression is controlled In Vitro by 
demethylating drugs
Epigenetic silencing of miR129-2 is associated 
with cancer and has been shown to be reversible by 
demethylating drugs, including 5-Azacytidine (5-Aza) 
[18]. 5-Aza is a DNA methyl-transferase inhibitor that 
has also been used successfully in epigenetic modification 
of SOX2 in adult malignant glioma cells [19]. We used 
PDGFB mouse cells and show that treatment with 5-Aza 
Figure 2: nG2 overexpression in PdGFb and PdGFb/H3.3 K27M/p53-/- mouse models. (a) In mouse, expression of NG2 in 
PDGFB mouse was limited to brainstem tumor (dotted area). (b) Sporadic expression of NG2 across brainstem and cerebellum of normal 
mouse. (c) Injection of NSG SCID mouse with mouse DIPG cells that are H3.3.K27 mutant and have PDGFB overexpression and p53 
deletion resulted in overexpression of NG2 (dotted area). (d) In the adjacent normal brain tissue of NSG SCID mouse injected with PDGFB/
H3.3.K27M/p53-/- cells, NG2 overexpression was not detected. Insets are 40 × magnifications of the corresponding panel. Scale bar: 200 
µM.
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Figure 3: nG2 upregulation in dIPG is partially due to hypermethylation and downregulation of its regulatory 
micrornA, mir129-2. (a) Luciferase vector with 3’-UTR sequence of NG2 cloned downstream of the firefly luciferase gene (Luc-
3’UTR) and plasmid vector with miR129-2 sequence were used. PDGFB mouse neurospheres were transfected in triplicates with luciferase 
and miR129-2 vectors, as shown, and luciferase expression was determined. Co-expression of Luc-3’UTR of NG2 and miR129-2 resulted 
in significant downregulation of luciferase expression as compared to cells transfected with luc-3’UTR and empty vector. P < 0.05 was 
considered significant. (b) PDGFB mouse neurospheres were transfected with miR129-2 or NG2-shRNA plasmids. Upregulation of either 
miR129-2 or NG2-shRNA resulted in NG2 downregulation in vitro when compared to empty vector or control shRNA treated cells. (c) 
Human DIPG cells, SF8628, were transduced with GFP expressing pCDH-control or pCDH-miR129-2 lentivirus. Immunofluorescence 
analysis by confocal microscopy revealed upregulation of miR129-2 (indicated by GFP) resulted in NG2 (red) downregulation in vitro 
when compared to control transduced cells. DAPI was used to stain nuclei. Scale bar = 5 µm. (d) Average expression of miR129-2 as 
assessed by RT-PCR (*miR129) or illumina expression chip assay (miR129), miR129 hypermethylation (miR129 me), and NG2 mRNA 
levels in human DIPG compared to adjacent normal. miR129-2 is shown to be downregulated in DIPG as assessed by RT-PCR and illumina 
chip assays. Hypermethylation of miR129-2 at four or more CpG sites corresponding to miR129-2 promoter were detected in 57% of 
DIPGs. As expected, downregulation of miR129-2 due to hypermethylation resulted in upregulation of NG2 mRNA as detected by NG2 
mRNA using illumina platform. (e) To reverse miR129-2 hypermethylation, PDGFB mouse neurospheres were treated with 5-Azacytidine, 
a DNA methyl-transferase inhibitor drug. NG2 expression decreased in mouse tumor cells when treated with 10-30 µM 5-Azacytidine as 
compared to untreated cells. NG2 expression in each sample was normalized to corresponding GAPDH signal and average NG2 expression 
from three experiments was plotted. 
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results in a significant downregulation of NG2 expression 
in these as compared to untreated cells (Figure 3e). 
nG2 Knockdown decreases cellular Migration 
In Vitro
In order to study the role of NG2 in cellular 
migration, we expanded PDGFB mouse BSG cells in vitro 
to form adherent monolayers. Scratch invasion assay, an 
established in vitro method that measures migration of 
adhered cells across the mechanically induced wound 
was performed [20], where cells were transfected with 
NG2-shRNA, miR129-2, or treated with demethylating 
drug 5-Aza (Supplementary Figure 3). Comparisons were 
done to cells treated with vehicle, control shRNA, or with 
empty vectors. We observed a significant reduction in NG2 
expression that corresponds to decreased cell invasion in 
all treated cells compared to controls (Supplementary Fig 
3). Specifically, treatment with NG2-shRNA, miR129-
2 and 5-Aza resulted in 51% (p < 0.001), 51% (p < 
0.001) and 82.5% (p < 0.001) cell invasion inhibition, 
respectively. Treatment with NG2-shRNA and miR129-
2 resulted in a very similar reduction in cell invasion 
(51%), which may rule out an off-target effect of the two 
constructs. 
Mitotic dIPG cells exhibit symmetric nG2 
expression resulting in co-expression of 
oligodendrocyte and Astrocyte Markers
To study the role of NG2 expression in 
gliomagenesis, we studied mitotically active mouse 
and human glioma cells. NG2 expression is typically 
asymmetric in non-malignant dividing stem cells, resulting 
in only one daughter cell ‘inheriting’ NG2 expression [13]. 
However, in glioma cells, NG2 expression is symmetric 
(inherited by both daughter cells), resulting in an increased 
population of uncommitted stem cells within the tumor 
[13]. To evaluate the NG2 expression pattern in DIPGs, 
we expanded human primary DIPG cells as well as 
neurospheres obtained from PDGFB mouse. Cells were 
fixed and stained using an antibody against NG2 and 
monitored for NG2 expression and distribution in dividing 
cells. Our immunocytochemical assays showed symmetric 
and equal expression of NG2 in both daughter cells of 
mouse cells and two human DIPG (SF8628, SUDIPGVI) 
neurospheres (Figure 4a). Symmetric NG2 expression was 
observed in 100% of dividing tumor cells, a characteristic 
previously reported in other gliomas [13].
To test the potential differentiation of NG2 
expressing cells into astrocytes or oligodendrocytes 
in vitro, human primary DIPG and mouse cells were 
expanded in culture. Immunocytochemical assays using 
antibodies for oligodendrocyte (Olig2) and astrocyte 
(GFAP) markers were performed (Figure 4b). We detected 
the presence of both GFAP and Olig2 in mitotic DIPG 
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Figure 4: Mouse and human dIPG neurospheres exhibit symmetric nG2 expression in vitro and are immature stem 
cells co-expressing oligodendrocyte (olig2) and astrocyte (GFAP) markers. (a) PDGFB mouse tumor neurospheres (Mouse) 
and human primary DIPG cells (SF8628 and SUDIPGVI) were grown and stained using NG2 antibody (red) and DAPI (blue) nuclear 
staining. NG2 is equally expressed in dividing cells suggesting that its expression is defective (symmetric) in mitotic cells. Scale bar = 5 
µm. (b) PDGFB mouse tumor (Mouse) and SF8628 human DIPG primary cells were expanded in culture and immunostained for DAPI 
(nuclear), oligodendrocyte marker (Olig2, green), NG2 (red), and astrocyte marker (GFAP, magenta). Confocal microscopy was used to 
assess expression of above-mentioned proteins in mitotic cells. Scale bar = 5 µM 
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cells that determine symmetric NG2 expression (Figure 
4b). Although pediatric brainstem gliomas are historically 
classified as astrocytic [21, 22], these results are consistent 
with a recent finding that oligodendrocyte progenitors 
may contribute to the formation of pediatric DIPG [7]. 
Further analysis using flow cytometry confirmed co-
expression of Olig2, GFAP and NG2 (Supplementary 
Figure 4). We observed that fifty percent (55.8%) of mouse 
neurospheres co-express Olig2 and NG2, 54% co-express 
NG2 and GFAP, and 55.6% co-express GFAP and Olig2 
(Supplementary Figure 4). These results suggest a lack of 
terminal differentiation in NG2 expressing cells in DIPG.
nG2 expressing neurospheres are neoplastic 
In Vivo and result in Highly Aggressive Pontine 
tumors
To test the tumorigenicity of NG2 expressing 
cells in vivo, and to approximate the anatomical 
microenvironment of human DIPGs, we injected 
(100,000-150,000) NG2 expressing PDGFB mouse tumor 
neurospheres (Figure 5a-5c) orthotopically into the pons 
of 2-day old (P2) Balb/C mice and monitored for signs 
of tumor extension, including cerebellar ataxia [23]. 
Mice were euthanized at P21 and brainstems stained by 
Figure 5: orthotopic injection of nG2 expressing cells causes aggressive brainstem tumors in vivo resulting in a robust 
murine model of dIPG. (a) NG2 expressing neurospheres were isolated from PDGFB mouse pontine tumor and expanded in culture 
and stained for NG2 (red) and DAPI (blue) (b and c). Neurospheres were then injected into the brainstems of two-day-old (P2) mice. Whole 
brain was obtained at 3 weeks post injection and subjected to H&E staining (d-g). Injected cells show an infiltrative pattern of growth (g, 
arrow) at the site of injection. H&E staining also showed a large infiltrating tumor within pons (region p in d). 10 × magnifications (e-f) 
revealed the highly cellular tumor within the pons (e) that exhibits characteristics of DIPGs including tumor vascularity (f, arrows). Injected 
cells were infiltrated through the pons and away from the injection site (g, arrow). This pontine tumor is positive for the astrocytic marker 
GFAP (h), proliferation marker Ki67 (i), PDGFRβ (j), PDGFRα (k), and NG2 (l). Scale bar = 100 µM 
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H&E for analysis by a neuropathologist (Figure 5d-5g). 
We found that 77.8% (14 of 18) of mice had detectable, 
infiltrating pontine tumors by P21. When left untreated, 
100% of mice died within 8 weeks post injection due to 
tumor growth as assessed by necropsy and examination 
by a neuropathologist. Histological examination of the 
mice brainstems showed infiltration of injected tumor 
cells within the pons (p) (Figure 5d), distal to the injection 
site (Figure 5g). The pontine tumors demonstrated 
histopathological characteristics of pediatric DIPGs, 
including hypercellularity, glial atypia, increased tumor 
vascularity and true microvascular proliferation (Figure 
5e and 5f). Immunohistochemical analysis of tumor tissue 
demonstrated upregulation of NG2, Ki67 (proliferation 
marker), PDGFRα, PDGFRβ and GFAP (Figure 5h-5l). 
nG2 expression is reduced In Vivo using 
targeted Microrna strategy
To determine whether we can reduce NG2 
expression in vivo, we used NG2-dsRed transgenic 
mice that express dsRed under the control of NG2 
promoter [24]. Nine days old (P9) NG2-dsRed mice 
were injected orthotopically with miR129-2 and GFP 
expressing lentivirus on the right hemisphere, and with 
GFP only expressing lentivirus (Control) on contralateral 
hemisphere. Mice were sacrificed two weeks post-
injection and brain sections were examined using confocal 
microscopy (Figure 6). GFP signal (green) was detected 
on both orthotopic injected hemispheres indicating in 
Figure 6: mir129-2 targets and downregulates nG2 in vivo. Brain sections from NG2-dsRed mice were analyzed 2 weeks after 
the intracranial injections with control lentiviral vector on left side and lentiviral vector harboring miR129-2 on right side. Detection of 
the green signal (GFP) indicates in vivo transduction of either control or miR129-2. Area enclosed by dotted line in 10 × image (Scale 
bar: 100 µM) represents the site of injection. 40 × magnification images (Scale bar: 10 µM) of boxed area in merged images are shown to 
demonstrate the downregulation of NG2 (red) in miR129-2 (green) transduced cells (arrows) while control transduced cells are expressing 
normal levels of NG2.
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vivo transduction of lentiviral vector. Examination of 
the right hemisphere injected with miR129-2 lentivirus 
indicated non to low expression of NG2 in cells 
transduced by miR129-2 as judged by GFP and dsRed 
expression. However, in the contralateral hemisphere 
injected with GFP only control lentivirus, no reduction in 
NG2 expression was observed indicating the suitability 
of miR129-2 as a potential therapeutic molecule for 
regulating NG2 expression in vivo (Figure 6). 
dIscussIon
Our study shows NG2 expression to be associated 
with 78% of our DIPG cohort. This observation is in 
line with previous measures of NG2 overexpression in a 
variety of cancers, including melanoma [25], glioblastoma, 
and lymphoid leukemia [11, 26, 27]. Moreover, NG2 
expression has been shown to correlate with increased 
glioma malignancy [10, 28, 29]. NG2 also binds to 
collagen VI and laminin 2, and NG2 expressing cells 
migrate more effectively on collagen and laminin 2 coated 
surfaces compared to NG2 null cells [30]. Since collagen 
VI and laminin 2 are not abundant in brain parenchyma, 
tumor microvasculature and axonal processes may 
facilitate migration (and thus infiltration) of NG2 cells. 
Exploring NG2 and its molecular pathways may provide 
an opportunity for treating DIPGs by targeting factors that 
contribute to cellular infiltration. 
Our data suggests the role of miR129-2 in 
regulating NG2. We show that in DIPGs, significant 
hypermethylation of miR129-2 promoter results in miR-
129-2 downregulation. This correlates with increased 
NG2 mRNA and protein expression in 71.4% of studied 
DIPG specimens. Our study shows administration of the 
demethylating drug 5-Aza results in NG2 downregulation 
in vitro. 5-Aza is a DNA methyl-transferase inhibitor 
that has been used successfully for targeting miR129-2 
in gastric cancer [18] and for epigenetic modification of 
SOX2 gene in adult malignant glioma cells [19]. Given 
our findings that NG2 is highly expressed in a majority of 
pontine tumors, preclinical studies testing 5-Aza in murine 
models may be warranted.
Glial cells of the central nervous system are 
generally classified into three histologic subtypes: 
astrocytes, microglia, and oligodendrocytes. NG2 
expressing cells represent the largest number of dividing 
cells in the adult brain [31]. The observation that NG2 
expressing cells give rise to oligodendrocytes in the 
developing and mature CNS led to recognition of NG2 
expressing cells as oligodendrocyte progenitor cells 
(OPCs). However, the likelihood of NG2 expressing cells 
to generate oligodendrocytes or other committed cells is 
highly debated (reviewed by [32]). Experiments using 
a tamoxifen-inducible NG2 Cre-ER reporter transgenic 
mouse model demonstrated anatomic- and age-dependence 
of NG2 cell differentiation [33]. These experiments 
revealed that NG2 cells of postnatal brain develop into 
oligodendrocytes, whereas NG2 cells in embryonic brain 
generate a subset of astrocytes in the ventral forebrain 
in addition to oligodendrocytes. Our observation that 
NG2 positive cells co-express oligodendrocyte (Olig2) 
and astrocyte (GFAP) cell markers may suggest their 
pluripotent potential. However, GFAP expression does 
not always indicate astrocytic lineage since introduction 
of the transcription factor NF1A has been shown to 
induce GFAP expression and astrocytic phenotype in 
OPC-derived tumors [34]. Although NG2 expressing 
cells differentiate into astrocytes or oligodendrocytes 
depending on age and neuroanatomical location [33], 
terminal differentiation of these cells may be in disarray 
in DIPG. This dysregulation of cell differentiation may 
result in a population of pluripotent tumor progenitor cells 
leading to a highly infiltrative and lethal cancer. Using 
human and PDGFB mouse DIPG cells, we demonstrated 
dichotomous Olig2 and GFAP expression, which may 
indicate the uncommitted pluripotent state of these cells. 
However, our results are consistent with others suggesting 
oligodendrocyte lineage precursors as cells of origin for 
DIPGs [7, 35, 36].
Asymmetric cell division plays an important role in 
organism development by generating committed progeny 
while at the same time maintaining a pool of progenitor 
stem cells to facilitate further development. Recently, 
NG2 expressing oligodendrocytes, which are glioma 
tumor progenitors, have been shown to exhibit defective 
asymmetric cell division [13]. This abnormal, symmetric 
cell division results in over-population of oligodendroglial 
precursor cells with impaired terminal differentiation, 
leading to neoplasia. Our observation of symmetric 
division in NG2 expressing mouse tumor neurospheres 
as well as human DIPG primary cells is consistent with 
these findings. Further studies are required to assess the 
expansion of NG2 expressing cells in DIPGs and their role 
in tumor progression. 
We show that orthotopic injection of (150,000) 
NG2 expressing mouse cells into pons of P2 mice results 
in generation of a highly proliferative and infiltrative 
pontine tumor. More importantly, we demonstrate that 
this mouse model exhibits a short latency to tumor 
development (77.8% at three weeks post injection) making 
it representative of the aggressive clinical course of 
DIPG, and suitable for rapid testing in preclinical studies. 
Other published murine models of brainstem tumors 
have used similar number of cells (100,000-200,000 
cells) for intracranial injection [7, 16, 37]. Therefore, the 
number of injected cells is not contributing to the short 
latency. Due to its anatomic location and the difficulty in 
obtaining tissue for molecular study, DIPG is historically 
an understudied pediatric tumor. The NG2 murine model 
can be complementary to existing genetically engineered 
[16] and the xenograft [7] models to further characterize 
DIPG biology and advance towards improved diagnosis 
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and treatment. Furthermore, we show that in vivo targeting 
of NG2 by miR129-2 results in downregulation of NG2, 
providing a strong candidate for targeted therapy for 
regulating NG2 expression.
MAterIAls And MetHods
Human tissue specimens
Human DIPG specimens were obtained postmortem 
[38] in accordance with Institutional Review Board 
approvals (#4932; #3804). Patient identifiers were 
removed prior to evaluation, and a single sequential 
numerical identifier was assigned to each patient 
(Supplementary Table 1). All brain tumor diagnoses were 
made radiographically by a neuroradiologist. 
Mice
Balb/C, heterozygous J:Nu, NG2-dsRed, and 
NOD SCID gamma mice were purchased (JAX Mice 
and services) and used in accordance with approved 
institutional animal use and care protocols (IACUC #292-
12-05, #01429, #01335). Frozen murine brainstem glioma 
specimens were obtained from Oren Becher [16] and 
processed as described below.
Western blot analysis
Western blotting was performed as described 
before [8]. Briefly, tissue lysates were prepared in 1X 
SDS Laemmli sample buffer containing 1 mM DTT 
and protease inhibitors. After protein concentration 
determined, 20 µg protein from each sample was 
resolved on 4-12% gels by SDS-PAGE. Proteins were 
then electroblotted onto nitrocellulose membranes and 
probed with appropriate primary antibody for 1 h at 
room temperature. After incubation with corresponding 
HRP-conjugated secondary antibodies, membranes were 
washed and antigens were detected by autoradiography 
using an ECL kit.
Antibodies
The following dilutions were used: NG2-rabbit 
polyclonal antibody (EMD Millipore) at 1:1000 (Western), 
1:200 (immunofluorescence/immunohistochemistry) and 
1:100 (flow cytometry); PDGFRα at 1:500, PDGFRβ 
at 1:50 (Cell Signaling Technology); Ki67 (Abcam) at 
1:200; GFAP-chicken polyclonal antibody (Abcam) at 
1:1000 (immunofluorescence) and 1:100 (flow cytometry), 
Olig2-mouse monoclonal (EMD Millipore) at 1:200 
(immunofluorescence) and 1:100 (flow cytometry). HRP 
secondary antibodies (Kirkergaard and Perry laboratories) 
at 1:5000 dilution for western blotting and 1:200 dilution 
for immunohistochemistry, all Alexa labeled antibodies 
(Life Technologies) at 1:500 dilution. For flow cytometry, 
1 µg of Alexa 488 or Alexa 647 labeled antibodies and 
0.25 µg of PE cy 5.5 in 100 µl of sample was used.
Immunohistochemistry
Immunohistochemical analysis was performed 
on formalin fixed paraffin-embedded tissue sections as 
previously described [8]. Briefly, slides were first de-
paraffinized and blocked in 1% BSA. Primary binding was 
performed by incubating the slides for 1 h with appropriate 
primary antibodies diluted in blocking buffer. Antigen 
levels were then detected by incubation with HRP labeled 
secondary antibodies followed by DAB assay. 
cell culture
PDGFB and PDGFB/H3.3-K27M/p53-/- mouse 
neurospheres were grown from tumor tissue obtained from 
mouse pontine tumors [16, 17]. Cells were dissociated 
and expanded in culture in the presence of mouse 
NeuroCult basal media supplemented with 10% mouse 
cell proliferation supplement (Stem Cell Technologies), 
glutamine, penicillin-streptomycin, heparin (2 µg/mL), 
rm EGF (20 ng/mL) and rm FGF (10 ng/mL). PDGFB 
mouse monolayer adherent cells were developed by 
culturing neurospheres in DMEM media supplemented 
with 10% FBS, glutamine, and antibiotics. Human DIPG 
primary cells (SF8628) were obtained from Dr. Nalin 
Gupta [39]. SUDIPGIV and SUDIPGVI were obtained 
from Dr. Michelle Monje and cultured according to 
already established protocol [7]. HEK 293FT cells (Life 
Technologies) were commercially obtained. SF8628 and 
HEK 293FT cells were cultured in DMEM supplemented 
with 10% FBS, glutamine, and antibiotics. Treatment 
of cells with 5-Azacytidine (Sigma) was performed by 
adding 1000 × solution, freshly prepared in media. 
luciferase assay
PDGFB mouse neurospheres were seeded into 
6-well tissue culture plates (200,000/well) in complete 
media and maintained at 37oC for 24 h. The cells were 
then co-transfected in triplicates with empty vector or 
miR129-2(5’ CUUUUUGCGGUCUGGGCUUGC 3’) 
plasmid (Origene) and luciferase reporter construct 
(Origene) harboring 3’ UTR of NG2 downstream of 
luciferase gene, using XtremeGene HP transfection 
reagent (Roche). Control transfections were performed 
by transfecting cells with miR129-2 plasmid alone or 
luciferase reporter construct alone. After 72 h, cell lysates 
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were prepared and luciferase expression was determined 
using luciferase assay kit according to the manufacturer’s 
protocol (Promega).
nG2 knockdown with shrnA and mir129-2
PDGFB mouse neurospheres and adherent mouse 
tumor cells were transfected with NG2 specific shRNA 
(Origene) or control shRNA or miR129-2 plasmids or 
empty vector using XtremeGene HP transfection reagent, 
according to the manufacturer’s protocol (Roche). 
For stable transfection in adherent mouse tumor cells, 
media was replaced 48 h post-transfection with fresh 
media containing 0.5 µg/ml of Puromycin (Sigma) and 
selected for NG2 knock down by changing the puromycin 
containing media every 2 days. Stable cells for NG2 
knock down were collected and cultured starting from the 
day when untransfected cells showed 100% cell death in 
presence of puromycin. 
construction of mir129-2 lentiviral vector
Cloning of precursor sequence of miR 
129-2 (5’UGCCUUUCGCGAAUCUUUUU 
CUGUACAUAACUCAAUAGCCGGAAGCCCUUACC 
CCAAAAAGCAUUCGCGGAGGGCG 3’) into HIV 
based lentiviral vector, pCDH-EF1-MCS-BGH-PGK-
GFP-T2A-Puro vector (System Biosciences), was 
performed by GenScript. Briefly, miR129-2 precursor 
sequence from pmiR129-2 plasmid was isolated and 
cloned into pCDH-EF1-MCS-BGH-PGK-GFP-T2A-
Puro vector using EcoR1 and Not1 restriction sites. After 
sequence verification, E.coli were transformed with 
the right clone and vector was expanded by DNA mini-
preparation.
Production of lentivirus
Plasmids for 3rd generation lentiviral packaging 
system (pMDLg/pRRE, pRSV-Rev, pMD2.G) were 
purchased from Addgene. Six million HEK293FT cells 
were plated into T75 cell culture flasks 24 h before 
transfection. Using XtremeGene HP transfection reagent 
(60 µl), cells were co-transfected with 10 µg of control-
pCDH or pCDH-miR129-2 vectors and packaging 
plasmids. A total of 10 µg of DNA was used for packaging 
plasmids (5 µg of pMDLg/pRRE and 2.5 µg each of 
pRSV-Rev and pMD2.G). After overnight incubation, 
media was replaced with fresh media and maintained 
under normal growth conditions. Virus containing 
supernatant was collected after 24 h and fresh media was 
added to cells, which was collected again as virus after 
additional 24 h incubation. Viral supernatants were then 
concentrated using Millipore Amicon Ultracel 100K spin 
columns and titered using QuickTiter Lentivirus Titer Kit 
(Cell Biolabs).
lentiviral transduction of human dIPG primary 
cells
SF8628 cells were seeded into 6 well cell culture 
plates and maintained for 24 h under normal growth 
conditions. Media was then replaced with 2 ml of fresh 
media containing 5 µg/ml of polybrene and added 0.4 
million TU in 20 µl of control pCDH or pCDH miR129-2 
vectors to cells. 24 h post-transduction, virus containing 
media was replaced with fresh media and maintained 
under normal growth conditions for 48 h.
In vivo lentiviral transduction
NG2-dsRed pups of day P9 were anesthetized by 
inducing hypothermia. Injection area was sterilized and 
exact injection spot was marked 2 mm right or left to the 
sagittal suture and 1 mm posterior to the bregma. Using a 
26-gauge needle fitted to a gas tight Hamilton syringe, 2 µl 
(2×108 TU/ml) of pCDH-miR129-2 lentiviral vector was 
injected on the right side and pCDH control vector was 
injected on the left side of the same mouse. After recovery, 
animals were returned to their home cages and monitored 
daily. 
Immunofluorescence
Cells grown on poly-l-lysine and laminin coated 
chamber slides were washed with PBS, fixed in 10% 
neutral buffered formalin solution for 15 min, and 
permeabilized in 0.1% Triton X-100 for an additional 
10 min. Cells were then blocked in PBS containing 1% 
BSA for 1 h, followed by the incubation with primary and 
fluorescent tagged secondary antibodies. After washing 
in PBS, cells were briefly stained with 4’,6-Diamidino-
2-phenylindole (DAPI) and imaged using laser scanning 
confocal microscope (Zeiss) and ZEN 2009 software 
(Zeiss).
scratch assay
Adherent PDGFB mouse tumor cells were subjected 
to one of four experimental arms: NG2 knock-down 
with shRNA, transient transfection with mirR129-2, 
transfection with control shRNA, no treatment or empty 
vector. All treatment groups were serum starved for 24 h. 
Cell monolayer was then scraped in a straight line with 
a p200 pipet tip and washed with PBS to rinse away any 
floating cells. Control cells were then treated with either 
vehicle (media) or 10 µM 5-Azacytidine and imaged using 
10 × objective at 0 and 24 h time intervals and scratch area 
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measured using image J software. Percentage cell invasion 
was calculated as follows: Percent invasion = (At = 0 h ˗ At 
= ∆ h
)/At = 0 h × 100%, as described previously [40], where, 
At = 0 h is the area of the invasion measured 
immediately after scratching and A
t = ∆ h
 is the cell invasion 
area measured at 24 h after scratching. 
FAcs analysis
Cells were fixed with 2.5% neutral buffered formalin 
and permeabilized in 90% ice-cold methanol for 30 min on 
ice, washed and blocked using FACS buffer (0.5% BSA 
in PBS). A mixture of GFAP, NG2 and Olig2 antibodies 
diluted in FACS buffer was added to cells and incubated 
for 1 h at room temperature, washed, and incubated for 
30 min in fluorescent labeled secondary antibody mixture. 
Cells were then washed and re-suspended in FACS 
buffer and loaded into a FACS Calibur (BD Biosciences) 
followed by analysis using Flowjo software (Tree Star).
orthotopic injection of mouse neurospheres
Pups (P2) were used for intracranial injection. Area 
of injection was sterilized and a total of 150,000 live 
tumor cells in 2 μl volume were injected into the brainstem 
(2 mm posterior to the bregma at the midline position) of 
cold anesthetized pups using a 26-gauge needle fitted to 
a gas tight Hamilton syringe [16]. NG2 expressing cells 
were generated by expanding cells obtained from PDGFB 
expressing brainstem glioma mouse model [16]. 
 Qrt-Pcr for mir129-2 expression
TaqMan small RNA assays kit (Applied Biosystems) 
was used to quantify the expression of miR129-2 in 
human DIPG samples. Briefly, 10 ng of total RNA in a 
final volume of 15 µl including 100 mM dNTPs, 50U 
of Multiscribe Reverse Transcriptase, 5 × RT primer 
(provided in the kit) was incubated at 16˚C for 30 min, 
42˚C for 30 min followed by enzyme inactivation at 85˚C 
for 5 min. QPCR of miR129-2 was performed according 
to manufacturer’s instructions. The reaction was done in 
20 µl total volume with 1.33 µl of cDNA, 1 µl of TaqMan 
small RNA assay (20 ×), and 10 µl of TaqMan Universal 
PCR Master Mix. QPCR of RNU48 gene was used as a 
housekeeping control. Fold changes were obtained using 
comparative CT method.
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